Market Research Logo

Hepatitis Drug Development Pipeline Review, 2017

Hepatitis Drug Development Pipeline Review, 2017

Summary


Hepatitis is a contagious viral infection affecting the liver, which may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis typically include dialysis, organ transplant and blood transfusion and theoffspring of an infected mother also has high chances of contracting the disease.

Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; there are a total of seven products in development for hepatitis A, by four companies and two academic institutions. Beijing Minhai Biotechnology are fielding two pipeline products in this area, while all other companies are fielding only one. In hepatitis D there are a total of 12 products in development, by nine companies and one academic institution. Key companies operating in this pipeline space include EigerBioPharmaceuticalsand Replicor.

Many of the companies who are actively fielding products in the larger two hepatitis subtypes are simultaneously developing products for both.

There are a total of 182 products in development for hepatitis B, by 110 companies and 14 academic institutions. Key companies operating in this pipeline space include Arbutus Biopharma, F. Hoffmann-La Roche, Johnson & Johnson, Assembly Biosciences, Gilead Sciences and InstitutoButantan. There are a total of 199 products in development for hepatitis C, by 92 companies and 34 academic institutions. Key companies operating in this pipeline space include Merck & Co, AbbVie, Johnson & Johnson, Gilead Sciences, Cocrystal Pharma, Bristol-Myers Squibb and F. Hoffmann-La Roche.

While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.

The report Hepatitis Drug Development Pipeline Review, 2017, provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for hepatitis therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of hepatitis?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Hepatitis Report Coverage
    • Hepatitis A – Overview
    • Hepatitis B – Overview
    • Hepatitis C – Overview
    • Hepatitis D – Overview
  • Therapeutics Development
    • Hepatitis A
      • Table Figure 1: Number of Products under Development for Hepatitis A
      • Table Number of Products under Development for Hepatitis A
      • Table Figure 2: Number of Products under Development by Companies, Hepatitis A
      • Table Number of Products under Development by Companies, Hepatitis A
      • Table Figure 3: Number of Products under Development by Universities/Institutes, Hepatitis A
      • Table Number of Products under Development by Universities/Institutes, Hepatitis A
      • Table Products under Development by Companies, Hepatitis A
      • Table Products under Development by Universities/Institutes, Hepatitis A
    • Hepatitis B
      • Table Figure 4: Number of Products under Development for Hepatitis B
      • Table Number of Products under Development for Hepatitis B
      • Table Figure 5: Number of Products under Development by Companies, Hepatitis B
      • Table Number of Products under Development by Companies, Hepatitis B
      • Table Figure 6: Number of Products under Development by Universities/Institutes, Hepatitis B
      • Table Number of Products under Development by Universities/Institutes, Hepatitis B
      • Table Products under Development by Companies, Hepatitis B
      • Table Products under Development by Universities/Institutes, Hepatitis B
    • Hepatitis C
      • Table Figure 7: Number of Products under Development for Hepatitis C
      • Table Number of Products under Development for Hepatitis C
      • Table Figure 8: Number of Products under Development by Companies, Hepatitis C
      • Table Number of Products under Development by Companies, Hepatitis C
      • Table Figure 9: Number of Products under Development by Universities/Institutes, Hepatitis C
      • Table Number of Products under Development by Universities/Institutes, Hepatitis C
      • Table Products under Development by Companies, Hepatitis C
      • Table Products under Development by Universities/Institutes, Hepatitis C
    • Hepatitis D
      • Table Figure 10: Number of Products under Development for Hepatitis D
      • Table Number of Products under Development for Hepatitis D
      • Table Figure 11: Number of Products under Development by Companies, Hepatitis D
      • Table Number of Products under Development by Companies, Hepatitis D
      • Table Number of Products under Development by Universities/Institutes, Hepatitis D
      • Table Products under Development by Companies, Hepatitis D
      • Table Products under Development by Universities/Institutes, Hepatitis D
  • Therapeutics Assessment
    • Hepatitis A
      • Table Number of Products by Stage and Target, Hepatitis A
      • Table Figure 12: Number of Products by Molecule Types, Hepatitis A
      • Table Figure 13: Number of Products by Stage and Molecule Types, Hepatitis A
      • Table Number of Products by Stage and Molecule Type, Hepatitis A
    • Hepatitis B
      • Table Figure 14: Number of Products by Top 10 Targets, Hepatitis B
      • Table Figure 15: Number of Products by Stage and Top 10 Targets, Hepatitis B
      • Table Number of Products by Stage and Target, Hepatitis B
      • Table Figure 16: Number of Products by Top 10 Mechanism of Actions, Hepatitis B
      • Table Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B
      • Table Number of Products by Stage and Mechanism of Action, Hepatitis B
      • Table Figure 18: Number of Products by Top 10 Routes of Administration, Hepatitis B
      • Table Figure 19: Number of Products by Stage and Top 10 Routes of Administration, Hepatitis B
      • Table Number of Products by Stage and Route of Administration, Hepatitis B
      • Table Figure 20: Number of Products by Top 10 Molecule Types, Hepatitis B
      • Table Figure 21: Number of Products by Stage and Top 10 Molecule Types, Hepatitis B
      • Table Number of Products by Stage and Molecule Type, Hepatitis B
    • Hepatitis C
      • Table Figure 22: Number of Products by Top 10 Targets, Hepatitis C
      • Table Figure 23: Number of Products by Stage and Top 10 Targets, Hepatitis C
      • Table Number of Products by Stage and Target, Hepatitis C
      • Table Figure 24: Number of Products by Top 10 Mechanism of Actions, Hepatitis C
      • Table Figure 25: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis C
      • Table Number of Products by Stage and Mechanism of Action, Hepatitis C
      • Table Figure 26: Number of Products by Routes of Administration, Hepatitis C
      • Table Figure 27: Number of Products by Stage and Routes of Administration, Hepatitis C
      • Table Number of Products by Stage and Route of Administration, Hepatitis C
      • Table Figure 28: Number of Products by Top 10 Molecule Types, Hepatitis C
      • Table Figure 29: Number of Products by Stage and Top 10 Molecule Types, Hepatitis C
      • Table Number of Products by Stage and Molecule Type, Hepatitis C
    • Hepatitis D
      • Table Figure 30: Number of Products by Targets, Hepatitis D
      • Table Figure 31: Number of Products by Stage and Targets, Hepatitis D
      • Table Number of Products by Stage and Target, Hepatitis D
      • Table Figure 32: Number of Products by Mechanism of Actions, Hepatitis D
      • Table Figure 33: Number of Products by Stage and Mechanism of Actions, Hepatitis D
      • Table Number of Products by Stage and Mechanism of Action, Hepatitis D
      • Table Figure 34: Number of Products by Routes of Administration, Hepatitis D
      • Table Figure 35: Number of Products by Stage and Routes of Administration, Hepatitis D
      • Table Number of Products by Stage and Route of Administration, Hepatitis D
      • Table Figure 36: Number of Products by Molecule Types, Hepatitis D
      • Table Figure 37: Number of Products by Stage and Molecule Types, Hepatitis D
      • Table Number of Products by Stage and Molecule Type, Hepatitis D
  • Companies Involved in Therapeutics Development
    • Hepatitis A
      • Table Hepatitis A – Pipeline by Beijing Minhai Biotechnology Co Ltd
      • Table Hepatitis A – Pipeline by Indian Immunologicals Ltd
      • Table Hepatitis A – Pipeline by Sinovac Biotech Ltd
      • Table Hepatitis A – Pipeline by Zydus Cadila Healthcare Ltd
    • Hepatitis B
      • Table Hepatitis B – Pipeline by Abivax SA
      • Table Hepatitis B – Pipeline by AiCuris GmbH & Co KG
      • Table Hepatitis B – Pipeline by AIMM Therapeutics BV
      • Table Hepatitis B – Pipeline by Akshaya Bio Inc
      • Table Hepatitis B – Pipeline by Alnylam Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by Altimmune Inc
      • Table Hepatitis B – Pipeline by Altravax Inc
      • Table Hepatitis B – Pipeline by Amarna Therapeutics BV
      • Table Hepatitis B – Pipeline by Arbutus Biopharma Corp
      • Table Hepatitis B – Pipeline by Arcturus Therapeutics Inc
      • Table Hepatitis B – Pipeline by Arrowhead Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by Assembly Biosciences Inc
      • Table Hepatitis B – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd
      • Table Hepatitis B – Pipeline by Beijing Minhai Biotechnology Co Ltd
      • Table Hepatitis B – Pipeline by Benitec Biopharma Ltd
      • Table Hepatitis B – Pipeline by Biological E Ltd
      • Table Hepatitis B – Pipeline by BioStar Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by Bolder Biotechnology Inc
      • Table Hepatitis B – Pipeline by BrightGene Bio-Medical Technology Co Ltd
      • Table Hepatitis B – Pipeline by Bukwang Pharm Co Ltd
      • Table Hepatitis B – Pipeline by CaroGen Corp
      • Table Hepatitis B – Pipeline by Celltrion Inc
      • Table Hepatitis B – Pipeline by Chong Kun Dang Pharmaceutical Corp
      • Table Hepatitis B – Pipeline by Chromis Therapeutics Inc
      • Table Hepatitis B – Pipeline by Cocrystal Pharma Inc
      • Table Hepatitis B – Pipeline by ContraVir Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by CyTuVax BV
      • Table Hepatitis B – Pipeline by Dicerna Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by Dong-A Socio Holdings Co Ltd
      • Table Hepatitis B – Pipeline by Dynavax Technologies Corp
      • Table Hepatitis B – Pipeline by Ensemble Therapeutics Corp
      • Table Hepatitis B – Pipeline by Enyo Pharma SA
      • Table Hepatitis B – Pipeline by eTheRNA Immunotherapies NV
      • Table Hepatitis B – Pipeline by F. Hoffmann-La Roche Ltd
      • Table Hepatitis B – Pipeline by GeneCure LLC
      • Table Hepatitis B – Pipeline by GeoVax Labs Inc
      • Table Hepatitis B – Pipeline by Gilead Sciences Inc
      • Table Hepatitis B – Pipeline by GlaxoSmithKline Plc
      • Table Hepatitis B – Pipeline by Green Cross Corp
      • Table Hepatitis B – Pipeline by Hanmi Pharmaceuticals Co Ltd
      • Table Hepatitis B – Pipeline by Humabs BioMed SA
      • Table Hepatitis B – Pipeline by Huons Co Ltd
      • Table Hepatitis B – Pipeline by Ildong Pharmaceutical Co Ltd
      • Table Hepatitis B – Pipeline by Immunotope Inc
      • Table Hepatitis B – Pipeline by Indian Immunologicals Ltd
      • Table Hepatitis B – Pipeline by Intellia Therapeutics Inc
      • Table Hepatitis B – Pipeline by Ionis Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by ISA Pharmaceuticals BV
      • Table Hepatitis B – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd
      • Table Hepatitis B – Pipeline by Johnson & Johnson
      • Table Hepatitis B – Pipeline by Kineta Inc
      • Table Hepatitis B – Pipeline by Leukocare AG
      • Table Hepatitis B – Pipeline by LG Chem, Ltd.
      • Table Hepatitis B – Pipeline by Ligand Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by Medivir AB
      • Table Hepatitis B – Pipeline by Mucosis BV
      • Table Hepatitis B – Pipeline by MultiCell Technologies Inc
      • Table Hepatitis B – Pipeline by Oncolys BioPharma Inc
      • Table Hepatitis B – Pipeline by Panacea Biotec Ltd
      • Table Hepatitis B – Pipeline by Pfenex Inc
      • Table Hepatitis B – Pipeline by PharmaEssentia Corp
      • Table Hepatitis B – Pipeline by Profarma
      • Table Hepatitis B – Pipeline by Profectus BioSciences Inc
      • Table Hepatitis B – Pipeline by Replicor Inc
      • Table Hepatitis B – Pipeline by Rodos BioTarget GmbH
      • Table Hepatitis B – Pipeline by Samjin Pharmaceutical Co Ltd
      • Table Hepatitis B – Pipeline by Sanofi
      • Table Hepatitis B – Pipeline by Sanofi Pasteur SA
      • Table Hepatitis B – Pipeline by Scynexis Inc
      • Table Hepatitis B – Pipeline by Shantha Biotechnics Ltd
      • Table Hepatitis B – Pipeline by Sinovac Biotech Ltd
      • Table Hepatitis B – Pipeline by Spring Bank Pharmaceuticals Inc
      • Table Hepatitis B – Pipeline by TCM Biotech International Corp
      • Table Hepatitis B – Pipeline by Theravectys SA
      • Table Hepatitis B – Pipeline by THEVAX Genetics Vaccine USA Inc
      • Table Hepatitis B – Pipeline by Tomegavax Inc
      • Table Hepatitis B – Pipeline by Transgene SA
      • Table Hepatitis B – Pipeline by Vaxine Pty Ltd
      • Table Hepatitis B – Pipeline by VBI Vaccines Inc
      • Table Hepatitis B – Pipeline by Vical Inc
      • Table Hepatitis B – Pipeline by ViroStatics srl
      • Table patitis B – Pipeline by VLP Biotech Inc
      • Table Hepatitis B – Pipeline by Zydus Cadila Healthcare Ltd
    • Hepatitis C
      • Table Hepatitis C – Pipeline by 3-V Biosciences Inc
      • Table Hepatitis C – Pipeline by AbbVie Inc
      • Table Hepatitis C – Pipeline by AIMM Therapeutics BV
      • Table Hepatitis C – Pipeline by Akshaya Bio Inc
      • Table Hepatitis C – Pipeline by Amarillo Biosciences Inc
      • Table Hepatitis C – Pipeline by Amarna Therapeutics BV
      • Table Hepatitis C – Pipeline by ARA Healthcare Pvt Ltd
      • Table Hepatitis C – Pipeline by Aviragen Therapeutics Inc
      • Table Hepatitis C – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd
      • Table Hepatitis C – Pipeline by Beta Pharma Inc
      • Table Hepatitis C – Pipeline by Biocad
      • Table Hepatitis C – Pipeline by Biotest Pharmaceuticals Corp
      • Table Hepatitis C – Pipeline by Biotron Ltd
      • Table Hepatitis C – Pipeline by Boehringer Ingelheim GmbH
      • Table Hepatitis C – Pipeline by Bolder Biotechnology Inc
      • Table Hepatitis C – Pipeline by Bristol-Myers Squibb Company
      • Table Hepatitis C – Pipeline by Cocrystal Pharma Inc
      • Table Hepatitis C – Pipeline by Conatus Pharmaceuticals Inc
      • Table Hepatitis C – Pipeline by ContraVir Pharmaceuticals Inc
      • Table Hepatitis C – Pipeline by DEKK-TEC Inc
      • Table Hepatitis C – Pipeline by Delpor Inc
      • Table Hepatitis C – Pipeline by F. Hoffmann-La Roche Ltd
      • Table Hepatitis C – Pipeline by Formune SL
      • Table Hepatitis C – Pipeline by Genecode AS
      • Table Hepatitis C – Pipeline by GeneCure LLC
      • Table Hepatitis C – Pipeline by Gilead Sciences Inc
      • Table Hepatitis C – Pipeline by GinkgoPharma Co Ltd
      • Table Hepatitis C – Pipeline by GlaxoSmithKline Plc
      • Table Hepatitis C – Pipeline by HanAll Biopharma Co Ltd
      • Table Hepatitis C – Pipeline by ImmunoBiology Ltd
      • Table Hepatitis C – Pipeline by ImmunoClin Corp
      • Table Hepatitis C – Pipeline by Immunotope Inc
      • Table Hepatitis C – Pipeline by Inovio Pharmaceuticals Inc
      • Table Hepatitis C – Pipeline by Integrated BioTherapeutics Inc
      • Table Hepatitis C – Pipeline by JN-International Medical Corp
      • Table Hepatitis C – Pipeline by Johnson & Johnson
      • Table Hepatitis C – Pipeline by Karyopharm Therapeutics Inc
      • Table Hepatitis C – Pipeline by Kineta Inc
      • Table Hepatitis C – Pipeline by Ligand Pharmaceuticals Inc
      • Table Hepatitis C – Pipeline by Medivir AB
      • Table Hepatitis C – Pipeline by Merck & Co Inc
      • Table Hepatitis C – Pipeline by Microbio Co Ltd
      • Table Hepatitis C – Pipeline by Microbiotix Inc
      • Table Hepatitis C – Pipeline by MultiCell Technologies Inc
      • Table Hepatitis C – Pipeline by NeuroVive Pharmaceutical AB
      • Table Hepatitis C – Pipeline by Novalex Therapeutics Inc
      • Table Hepatitis C – Pipeline by Novartis AG
      • Table Hepatitis C – Pipeline by NovaTarg Therapeutics Inc
      • Table Hepatitis C – Pipeline by Ono Pharmaceutical Co Ltd
      • Table Hepatitis C – Pipeline by Pfenex Inc
      • Table Hepatitis C – Pipeline by Pfizer Inc
      • Table Hepatitis C – Pipeline by PharmaEssentia Corp
      • Table Hepatitis C – Pipeline by Presidio Pharmaceuticals Inc
      • Table Hepatitis C – Pipeline by Profectus BioSciences Inc
      • Table Hepatitis C – Pipeline by Replicor Inc
      • Table Hepatitis C – Pipeline by Rodos BioTarget GmbH
      • Table Hepatitis C – Pipeline by Solon Eiendom ASA
      • Table Hepatitis C – Pipeline by SomaGenics Inc
      • Table Hepatitis C – Pipeline by Sorrento Therapeutics Inc
      • Table Hepatitis C – Pipeline by Sudershan Biotech Ltd
      • Table Hepatitis C – Pipeline by TaiGen Biotechnology Co Ltd
      • Table Hepatitis C – Pipeline by TaiwanJ Pharmaceuticals Co Ltd
      • Table Hepatitis C – Pipeline by Therapure Biopharma Inc
      • Table Hepatitis C – Pipeline by Theravectys SA
      • Table Hepatitis C – Pipeline by THEVAX Genetics Vaccine USA Inc
      • Table Hepatitis C – Pipeline by Vakzine Projekt Management GmbH
      • Table Hepatitis C – Pipeline by Vertex Pharmaceuticals Inc
      • Table Hepatitis C – Pipeline by WhanIn Pharmaceutical Co Ltd
      • Table Hepatitis C – Pipeline by Zylacta Corp
    • Hepatitis D
      • Table Hepatitis D – Pipeline by Alnylam Pharmaceuticals Inc
      • Table Hepatitis D – Pipeline by Eiger BioPharmaceuticals Inc
      • Table Hepatitis D – Pipeline by F. Hoffmann-La Roche Ltd
      • Table Hepatitis D – Pipeline by Globeimmune Inc
      • Table Hepatitis D – Pipeline by Replicor Inc
      • Table Hepatitis D – Pipeline by Rodos BioTarget GmbH
      • Table Hepatitis D – Pipeline by SomaGenics Inc
      • Table Hepatitis D – Pipeline by Spring Bank Pharmaceuticals Inc
  • Dormant Projects
    • Hepatitis A
      • Table Hepatitis A – Dormant Projects
    • Hepatitis B
      • Table Hepatitis B – Dormant Projects
    • Hepatitis C
      • Table Hepatitis C – Dormant Projects
    • Hepatitis D
      • Table Hepatitis D – Dormant Projects
  • Discontinued Products
    • Hepatitis B
      • Table Hepatitis B – Discontinued Products
    • Hepatitis C
      • Table Hepatitis C – Discontinued Products
    • Hepatitis D
      • Table Hepatitis D – Discontinued Products
  • Product Development Milestones
    • Hepatitis B
    • Hepatitis C
    • Hepatitis D
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report